This article contains content that is written like an advertisement. (March 2011) (Learn how and when to remove this template message)
The company focused on antigen-primed, dairy-derived health products. Immuron’ proprietary, technology enables it to rapidly develop polyclonal antibody and other proteins-based solutions to a range of important diseases.
Immuron specialises in nutraceutical, pharmaceutical and related therapeutic technology products, including Oral and GI Mucositis, Routine and Avian Influenza, - E. coli Travellers' diarrhoea (TD), Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD), and Anthrax containment.
In 2005, Anadis signed an agreement with Quebec's Baralex Inc. and Valeo Pharma Inc. for distribution of Travelan, a product by Anadis, in Canadian market.
- "Anadis". Australian Stock Exchange. 2007-06-05.[permanent dead link]
- Canada, Asia Pacific Foundation of. "Valeo Pharma, Baralex Sign Distribution Agreement with Australia's Anadis Ltd". Asia Pacific Foundation of Canada. Retrieved 2017-09-18.
|This biotechnology article is a stub. You can help Wikipedia by expanding it.|
|This pharmacy-related article is a stub. You can help Wikipedia by expanding it.|